| Biomarker ID | 1242 |
| PMID | 24240583 |
| Year | 2013 |
| Biomarker | iXip: [IgM] + [tPSA] |
| Biomarker Basis | Concentration Based |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Upregulated in PCa [PCa: 0.467 ± 0.160; Controls: 0.314 ± 0.098] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Prostate Cancer Vs Controls |
| Type of Biomarker | Diagnostic |
| Cohort | 160 people were selected for the study - 111 Controls and 49 Prostate Cancer Cases |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.787 |
| Accuracy | NA |
| Level Of Significance | p <0.001 |
| Method Used | ELISA |
| Clinical | No |
| Remarks | iXip is defined as the sigmoidal function of iXi. Which was represented as: iXi = β0 + β1 · PSA-IgMnorm + (β21 · (tPSA + 0.1))^β22; |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |